Oncology Clinical Trials Congress And Oncology Clinical Trials In Emerging Regions, 13-14 May 2013, Prague, Czech Republic
Clinical trials run by pharmaceutical and biotech companies have undergone major changes as a result of implementing adaptive designs to tailor a trial as it progresses. Supporters of Adaptive Clinical Trials argue they achieve a real reduction in costs and can significantly improve the overall clinical accuracy.
However, the successful implementation of an adaptive design involves managing complex relationships between clinicians, trial managers, statisticians, compliance managers and regulators. The advent of "personalized medicine" adds to the complexity, as it is not possible to design clinical trials as in the past.
Emmanuel Pham, Senior Director, Global R&D Statistics, IPSEN Innovation, France, speaking at Global Engage's Oncology Congress in Prague this May, argues that using preclinical data and appropriate statistical methods, it is possible to design clinical trials to make positive selection of right targets and right populations in phase 2, and to allow confirmation in phase 3. He believes that the translational sciences are key in this new approach, and require appropriate statistical treatment to give all their potency.
The Oncology Clinical Trials Congress and Oncology Clinical Trials in Emerging Regions take place in Prague 13 & 14 May, 2013. Over 100 people will attend. The meetings are collocated at the INTERCONTINENTAL PRAGUE HOTEL, Parizska 30, Prague, 110 00 Czech Republic.
Free places are available, please visit http://www.clinical-trials-events.com/oct/RegOffer.html
Adapted by MNT from original media release